WP Advisors LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 28,363 shares of the biopharmaceutical company’s stock after selling 944 shares during the period. Gilead Sciences comprises approximately 2.0% of WP Advisors LLC’s portfolio, making the stock its 14th biggest holding. WP Advisors LLC’s holdings in Gilead Sciences were worth $2,190,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of GILD. Northwest Bancshares Inc. boosted its stake in shares of Gilead Sciences by 8.9% during the third quarter. Northwest Bancshares Inc. now owns 28,816 shares of the biopharmaceutical company’s stock valued at $2,224,000 after acquiring an additional 2,344 shares during the last quarter. DnB Asset Management AS boosted its stake in shares of Gilead Sciences by 4.4% during the second quarter. DnB Asset Management AS now owns 156,552 shares of the biopharmaceutical company’s stock valued at $11,090,000 after acquiring an additional 6,600 shares during the last quarter. Swedbank boosted its stake in shares of Gilead Sciences by 103.7% during the third quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock valued at $301,596,000 after acquiring an additional 1,988,987 shares during the last quarter. Fairpointe Capital LLC acquired a new stake in shares of Gilead Sciences during the second quarter valued at $708,000. Finally, IFM Investors Pty Ltd boosted its stake in shares of Gilead Sciences by 15.8% during the third quarter. IFM Investors Pty Ltd now owns 68,466 shares of the biopharmaceutical company’s stock valued at $5,286,000 after acquiring an additional 9,342 shares during the last quarter. 78.23% of the stock is currently owned by institutional investors.
A number of analysts recently commented on GILD shares. Piper Jaffray Companies set a $85.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, September 12th. Mizuho reaffirmed a “buy” rating and set a $94.00 price objective on shares of Gilead Sciences in a research note on Friday, August 10th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research note on Wednesday, July 18th. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, October 11th. Finally, Evercore ISI reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Wednesday. Thirteen investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $87.84.
Shares of NASDAQ:GILD opened at $70.31 on Friday. The company has a current ratio of 3.47, a quick ratio of 3.39 and a debt-to-equity ratio of 1.36. Gilead Sciences, Inc. has a 12-month low of $64.27 and a 12-month high of $89.54. The stock has a market capitalization of $93.39 billion, a price-to-earnings ratio of 8.21, a price-to-earnings-growth ratio of -2.80 and a beta of 1.01.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The firm had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.44 billion. During the same period last year, the company earned $2.27 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 6.44 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.24%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s payout ratio is 26.64%.
In other news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $78.04, for a total value of $3,902,000.00. Following the transaction, the director now directly owns 3,067,762 shares in the company, valued at approximately $239,408,146.48. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.30% of the stock is currently owned by company insiders.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: Marijuana Stocks Future Looks Bright
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.